Sharemaestro Newsreel

Bristol Myers Squibb (BMY) Wins FDA Approval, Is The Stock Fully Priced?

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Bristol Myers Squibb (BMY) is back in focus after the FDA granted accelerated approval for ZENBEXUS in a multiple myeloma combination regimen, introducing …

Candel Therapeutics (NASDAQ:CADL) Stock Price Expected to Rise, Bank of America Analyst Says

Price-Driven Insight from (CRBP) for Rule-Based Strategy

This article provides a price-driven insight for Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP), outlining near-term and mid-term strong sentiment but a weak long-term outlook. It details specific trading strategies including position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis and support/resistance …

Bernstein Lifts Regeneron Price Target to $756, Stays on Sidelines

Bernstein has raised its price target for Regeneron Pharmaceuticals to $756 from $753, while maintaining a Market Perform rating, indicating a slightly more positive near-term outlook but not a fundamental shift in its investment thesis. This new target remains below the Wall Street consensus …

OSR Health (OSRH) cuts losses but faces sharp revenue drop and tight cash

What Does Stryker (SYK) Q1 Growth Mean If Costs Are Still Pressuring Earnings?

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Stryker (NYSE:SYK) reported strong first quarter growth, supported by underlying demand and a recovery from a prior cyber incident. The company highlighted organic growth across …

SS Innovations International (SSII) Reports Record Q2 Revenue of $13.9M, Up 39.4%

SS Innovations International (SSII) announced record second-quarter 2026 revenue of $13.9 million, a 39.4% increase year-over-year, driven by a 30.4% rise in SSi Mantra surgical robotic system installations. The company reported a gross profit of $7.1 million and a cumulative installed base of 224 …

HTFL Maintained by Morgan Stanley -- Price Target Raised to $40.

Why Eton Pharmaceuticals Is Top of the Class Today

Key Points Eton Pharmaceuticals beat on both top and bottom lines last night. Management is licensing a new drug, and raising guidance through the end of 2026.10 stocks we like better than Eton Pharmaceuticals › Eton Pharmaceuticals (NASDAQ: ETON) stock soared 41.9% through 2:15 …

Zoetis: The Growth Story Has Broken, But The Valuation Finally Makes Sense (NYSE:ZTS)

Bleichroeder LP Discloses Investment at MDxHealth SA with 33.2% Stake

Bleichroeder LP has disclosed a 33.2% stake in MDxHealth SA after purchasing 24,229,074 shares in a direct offering for $0.454 per share. This investment gives Bleichroeder significant influence and is subject to a 90-day lock-up period. The firm stated its intent for portfolio purposes …

Gilead Sciences (GILD) Could Be 8% Overvalued As AI Deal And Q2 Results Lift Shares

Gilead Sciences (GILD) is gaining investor attention due to a new AI collaboration with Nucleai and positive Q2 results, though some analyses suggest it might be overvalued by about 8%. The company is transitioning into a multi-platform biopharma, but differing valuation models present varied …

Citius Pharmaceuticals (CTXR) holders report 3.0M-share, 9.9% beneficial stake

CVI Investments, Inc. and Heights Capital Management, Inc. have reported a beneficial ownership of 3,008,529 common shares in Citius Pharmaceuticals (CTXR), which represents a 9.9% stake. This position primarily consists of shares issuable upon the exercise of warrants, subject to beneficial ownership limits of …

UFP Technologies (NASDAQ: UFPT) insider plans sale of 2,349 shares

UFP Technologies (NASDAQ: UFPT) has filed a Form 144 to register the planned sale of 2,349 shares of common stock through Merrill Lynch on or after August 14, 2026. The shares have an aggregate market value of $625,145.67 and represent a small fraction of …

American Century group reports 5.4% Emergent BioSolutions (EBS) ownership on Schedule 13G

American Century ETF Trust and its affiliates, including American Century Investment Management, Inc., American Century Companies, Inc., and the Stowers Institute for Medical Research, have reported passive ownership stakes in Emergent BioSolutions Inc. (EBS) common stock via a Schedule 13G filing. The ETF Trust …

Assembly Biosciences (NASDAQ:ASMB) Trading Up 8.2% on Strong Earnings

Assembly Biosciences (NASDAQ:ASMB) saw its shares rise by 8.2% after reporting better-than-expected quarterly earnings, with a loss of $0.20 per share against an anticipated $0.72 loss and revenue of $13.37 million surpassing estimates of $8.60 million. Analysts have a "Moderate Buy" consensus rating with …

Goldman Sachs Group (TNGX) discloses 6.0% beneficial stake in Tango Therapeutics

The Goldman Sachs Group, Inc. and its subsidiary Goldman Sachs & Co. LLC have disclosed a 6.0% beneficial ownership stake in Tango Therapeutics, Inc. (TNGX) through a Schedule 13G filing. This holding amounts to 9,742,402.80 shares and signifies shared voting and dispositive power over …

Twist Bioscience (TWST): ARK Investment Management reports 4.55M-share, 7.31% stake

ARK Investment Management LLC and its founder Catherine D. Wood have reported a beneficial ownership of 4,549,803 shares of Twist Bioscience Corp (TWST) common stock, representing 7.31% of the company's class. The filing, a Schedule 13G/A, indicates that ARK has sole voting power over …

Will Pennant’s Higher 2026 Guidance and Tucson Acquisition Change Pennant Group's (PNTG) Narrative

The Pennant Group (PNTG) reported strong Q2 2026 results with increased sales and net income, along with higher 2026 revenue guidance of US$1.17 billion to US$1.19 billion. The company also expanded its senior living portfolio by acquiring the River Centre Assisted Living community in …

Heartflow, Inc. Stock 12‑Month Price Target Raised to $43.5, Implies 40% Upside

Heartflow, Inc.'s stock 12-month price target has been increased to $43.5 from $36.62, representing a 40% potential upside based on its closing price on August 13. This revised target comes from estimates by 8 analysts, with forecasts ranging from $39 to $45 per share. …

Canopy Growth’s Kincardine Facility Secures EU-GMP Recertification

Canopy Growth's Kincardine, Ontario facility has received renewed EU-GMP certification from a German authority, critical for exporting medical cannabis to Germany. This recertification highlights the facility's quality and reliability, supporting Canopy Growth's expanding presence in the European market. The Kincardine facility, a 440,000-square-foot greenhouse, …

Kura Oncology (NASDAQ:KURA) Stock Price Up 8% on Analyst Upgrade

Kura Oncology (NASDAQ:KURA) saw its stock price rise 8% following an analyst upgrade from Wedbush, which increased its price target to $38 from $36 while maintaining an "outperform" rating. The company's Q2 results surpassed expectations with a narrower loss and higher revenue, driven by …

Why Oscar Health (OSCR) Stock Is Up Today

Molina Healthcare (MOH) Is Up 7.2% After Strong Q1 Results And Clearer Medicaid Funding Outlook

Cardinal Health CEO details M&A strategy and growth

Jason Hollar, Cardinal Health (CAH) CEO joins Yahoo Finance Executive Editor Brian Sozzi to detail how M&A strategy, specialty pharma growth, and drug volume dynamics are driving profits. Video Transcript 00:00 Speaker A Where do you want to take this business with acquisitions? 00:02 …

ImmuCell Corporation 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:ICCC) 2026-08-14

Why (TIL) Price Action Is Critical for Tactical Trading

This article analyzes Instil Bio Inc. (NYSE: TIL) using AI models to suggest trading strategies based on price action. It identifies neutral readings in shorter horizons, potentially signaling an easing of a long-term weak bias, and highlights compelling upside potential with no remaining resistance …

Kestra Medical Technologies (KMTS) Nears Its Fair Value, Is The Stock Already Fully Valued?

Kestra Medical Technologies (KMTS) has seen recent positive share price momentum, with its stock closing at US$27.74. While a common narrative suggests the stock is undervalued with a fair value of $28 based on ambitious growth assumptions, other metrics like the P/S ratio indicate …

Liquidity Mapping Around (SRZN) Price Events

The article provides a detailed analysis of Surrozen Inc. (NASDAQ: SRZN) stock, highlighting strong sentiment across all horizons and an exceptional 86.7:1 risk-reward setup. It outlines three distinct AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—tailored for different risk profiles and holding periods, along …

Lantern Pharma (LTRN) Advances AI-Driven Oncology Pipeline Amid Valuation Challenges

Bionano Genomics (BNGO) investor discloses 9.9% position via warrants

CVI Investments, Inc. and Heights Capital Management, Inc. have disclosed a 9.9% beneficial ownership in Bionano Genomics (BNGO) through warrants. This position, amounting to 1,307,135 shares, is subject to ownership caps of 4.99% and 9.99% for different portions of the warrants. The ownership percentage …

AN2 Therapeutics (ANTX) director reports gift of 405,880 shares and 145,538 held

AN2 Therapeutics director Joseph S. Zakrzewski reported a bona fide gift of 405,880 shares of common stock, which were previously held indirectly through the Z3 Trust. He disavows beneficial ownership of these gifted shares. Following this transaction, Zakrzewski directly holds 145,538 shares of AN2 …

CVRx, Inc. (CVRX) investor Jorey Chernett discloses 5.5% beneficial stake

Investor Jorey Chernett has disclosed a 5.5% beneficial ownership stake in CVRx, Inc. (CVRX), holding 1,461,750 shares of common stock. This ownership grants Chernett sole voting and dispositive power over these shares, based on CVRx's 26,641,597 outstanding shares as of July 30, 2026. The …

Waystar Holding Corp. (WAY) awards 162,112 RSUs to Chief Financial Officer

Waystar Holding Corp. (WAY) has granted 162,112 restricted stock units (RSUs) to its Chief Financial Officer, Alpana Wegner, on July 24, 2026. These RSUs will vest over time, with 6.25% vesting quarterly during the first year and 25% annually thereafter until July 22, 2030, …

Cormorant Asset Management (CABA) discloses 10M-share Cabaletta Bio stake

Cormorant Asset Management, LP and Bihua Chen have disclosed a 5.95% beneficial stake in Cabaletta Bio, Inc. (CABA), totaling 10,000,000 shares. This stake comprises 5,000,000 common shares and warrants to purchase an additional 5,000,000 shares, with both parties holding shared voting and dispositive power. …

Praxis Precision Medicines (PRAX): Orbis, Allan Gray disclose 5.5% ownership stake

Orbis Investment Management Ltd and Allan Gray Australia Pty Ltd have jointly disclosed a 5.5% ownership stake in Praxis Precision Medicines (PRAX), amounting to 1,529,788 shares of common stock as of June 30, 2026. Orbis holds the majority with 1,526,680 shares, while Allan Gray …